评估挽救性化疗治疗复发/难治侵袭性淋巴瘤相关的间接医疗成本：加拿大癌症临床试验组（CCTG）LY.12 临床试验的亚组分析。
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.
机构信息
Canadian Cancer Trials Group, Queen's University, Kingston, ON K7L 3N6, Canada.
出版信息
Curr Oncol. 2021 Mar 17;28(2):1256-1261. doi: 10.3390/curroncol28020119.
Abstract
We conducted an analysis of indirect costs alongside the LY.12 randomized trial in patients with relapsed or refractory (R/R) aggressive non-Hodgkin lymphoma (NHL). Lost productivity data for Canadian patients and caregivers in the trial were collected at baseline and with each chemotherapy cycle pre-transplant, using an adapted Lost Productivity questionnaire. Mean per patient indirect costs were CAD 2999 for patients in the GDP arm and CAD 3400 in the DHAP arm. A substantial majority was not working or had to reduce their workload during this treatment time. Salvage chemotherapy for R/R aggressive NHL is associated with significant indirect costs to patients and their caregivers.
摘要
我们在 LY.12 随机试验中对复发或难治性（R/R）侵袭性非霍奇金淋巴瘤（NHL）患者的间接成本进行了分析。使用改良后的生产力损失问卷，在试验中收集了加拿大患者和护理人员在基线和每次移植前化疗周期的生产力损失数据。GDP 组每位患者的平均间接成本为 2999 加元，DHAP 组为 3400 加元。绝大多数患者在治疗期间无法工作或不得不减少工作量。挽救性化疗治疗 R/R 侵袭性 NHL 会给患者及其护理人员带来巨大的间接成本。
相似文献
1
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.
Curr Oncol. 2021 Mar 17;28(2):1256-1261. doi: 10.3390/curroncol28020119.
2
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
J Natl Cancer Inst. 2015 Apr 13;107(7). doi: 10.1093/jnci/djv106. Print 2015 Jul.
3
Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Pharmacol Rep. 2019 Jun;71(3):473-477. doi: 10.1016/j.pharep.2019.02.001. Epub 2019 Feb 6.
4
Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial.
Ann Oncol. 2017 Mar 1;28(3):622-627. doi: 10.1093/annonc/mdw653.
5
6
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Cancer Invest. 2008 May;26(4):401-6. doi: 10.1080/07357900701788098.
7
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ann Hematol. 2018 Sep;97(9):1619-1626. doi: 10.1007/s00277-018-3328-3. Epub 2018 Apr 16.
8
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
Cancer. 2004 Oct 15;101(8):1835-42. doi: 10.1002/cncr.20587.
9
Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Leuk Lymphoma. 1999 Nov;35(5-6):527-36. doi: 10.1080/10428199909169617.
10
Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.
Br J Haematol. 2024 Sep;205(3):881-890. doi: 10.1111/bjh.19555. Epub 2024 May 27.
引用本文的文献
1
The association of health care contact days with economic measures in the CCTG LY.12 trial.
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf165.
2
Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.
Oncologist. 2023 Sep 7;28(9):799-803. doi: 10.1093/oncolo/oyad128.
本文引用的文献
1
Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma.
Leuk Lymphoma. 2016 Nov;57(11):2636-43. doi: 10.3109/10428194.2016.1161187. Epub 2016 Apr 14.
2
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
J Natl Cancer Inst. 2015 Apr 13;107(7). doi: 10.1093/jnci/djv106. Print 2015 Jul.
3
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
J Clin Oncol. 2014 Nov 1;32(31):3490-6. doi: 10.1200/JCO.2013.53.9593. Epub 2014 Sep 29.
4
Absenteeism and short-term disability associated with breast cancer.
Breast Cancer Res Treat. 2011 Nov;130(1):235-42. doi: 10.1007/s10549-011-1541-z. Epub 2011 May 13.
5
Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
Haematologica. 2005 Oct;90(10):1422-32.
6
The validity and reproducibility of a work productivity and activity impairment instrument.
Pharmacoeconomics. 1993 Nov;4(5):353-65. doi: 10.2165/00019053-199304050-00006.
7
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
N Engl J Med. 1995 Dec 7;333(23):1540-5. doi: 10.1056/NEJM199512073332305.
Zotero 插件